ms and semaglutide In adults with obesity but not diabetes, tirzepatide leads to significantly greater weight loss than over 72 weeks, nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms .spr.ly/6183SkuIL Developing and Validating a Simple,

Clinical trials show that GLP-1 agonists reduce appetite signaling in the brain's hypothalamus, which can support weight loss at any target level

Its important to remember that most of these side effects are mild to moderate in severity and typically resolve as your body adjusts to the medication over several weeks

Patients with inflammatory bowel disease considering semaglutide therapy should engage in comprehensive discussions with their healthcare team, ideally involving both their gastroenterologist and the physician prescribing the medication

Reno AM, et al

The UK Association of Anaesthetists published comprehensive multidisciplinary consensus in January 2025, recommending that GLP-1 receptor agonists be continued before surgery with individualised risk assessment [42]